Navigation Links
TechniScan Signs Agreement With Texas-Based Company to Co-Develop A New Version of Its Breast Imaging Device

SALT LAKE CITY, Jan. 18, 2011 /PRNewswire/ -- TechniScan (OTC Bulletin Board: TSNI), a medical device company engaged in the development and commercialization of an automated 3D breast ultrasound imaging system, announced today that it has signed a Product Development Agreement with Austin, Texas based Womens3D, Inc. worth a minimum of $1.5 million.

TechniScan and Womens3D will co-develop technology specifically for Womens3D's proposed target market that is directed toward women's health practices.  

Under the terms of the agreement, Womens3D acquired a prototype of the TechniScan WBU system for $250,000 and contemplates contributing at least $1.25 million more to support development of a specialized whole breast ultrasound imaging system based on the TechniScan Warm Bath Ultrasound (WBU) product now in clinical testing. In addition, TechniScan will supply technical support of the product and customization of the imaging network applications that will be used in part to store and transmit the image files.

"As a part of the Development Agreement, we purchased a prototype WBU system for evaluation, and we are now very excited to be working with TechniScan and welcome their expertise as we address the needs of the developing markets in women's health," said Scott Sanders, chief executive officer of Womens3D.  

Womens3D's Chief Science Officer, Mark Lenox, Ph.D., formerly part of the engineering team that performed the research and early development and commercialization of Positron Emission Tomography (PET) in nuclear medical imaging, conducted the technical evaluation of TechniScan's WBU system.  

TechniScan's Warm Bath Ultrasound (WBU) system is designed to capture three-dimensional images of the breast as a woman lies prone on a table while proprietary ultrasound technology in a warm water tank images the breast anatomy.  This new method of imaging produces diagnostic information that is not available with traditional hand-held ultrasound or whole breast ultrasound systems presently on the market.

"TechniScan is excited to be working with Womens3D on this development program, which potentially will open new markets for our equipment and add a valuable partner to our development efforts. Over the next one to two years we expect to complete the development of an ultrasound system for Womens3D based on our technology," said Dave Robinson, chief executive officer of TechniScan.

A more complete and detailed description of the Product Development Agreement is set forth in TechniScan's current report on Form 8-K filed today with the Securities and Exchange Commission.

About TechniScan

TechniScan, Inc., is a medical device company engaged in the development and commercialization of a non-invasive imaging tool designed to provide physicians with automated ultrasound images of the human breast. TechniScan's WBU™ imaging device is limited by U.S. law to investigational use, unless and until cleared by the FDA.  For more information, please visit

About Womens3D

Womens3D, Inc., is an early stage medical device company engaged in the development and commercialization of imaging solutions designed to provide women's health practices with powerful new tools that can deliver rapid and clinically effective diagnostic breast imaging at the point of care.  For more information please visit

Forward-Looking Statements Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Such statements may be identified by the use of words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "potential," "intend," and similar expressions.  Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of TechniScan, Inc. (the "company") to be materially different from those expressed or implied by such forward-looking statements.  The company's future operating results are dependent upon many factors, including risk factors discussed in the company's periodic filings with the Securities and Exchange Commission, which are available for review at, including the company's Annual Report on Form 10-K filed on March 22, 2010. The company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For More Information:
Dave Robinson
TechniScan Medical Systems
(801) 994-2965

SOURCE TechniScan
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors
2. TechniScan Cofounder to Speak at SPIE Medical Imaging Conference About Ground-Breaking Science Behind the Companys Ultrasound Technology
3. TechniScan Launches 3-D Breast Ultrasound Clinical Study in Freiburg University
4. Patent Awarded to the Design of TechniScans Unique 3-D Breast Imaging System
5. TechniScan Announces Adding Another Center to Worldwide Clinical Trials for New Breast Imaging System
6. TechniScan, Inc. Announces Restructuring of Convertible Debt
7. TechniScan Secures $10 Million Equity Financing Facility
8. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
9. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
10. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
11. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
Post Your Comments:
(Date:11/26/2015)... --> --> Juntendo University ... contrast weighting of MRI for patients with Multiple Sclerosis ... agreement with SyntheticMR in order to use SyMRI in clinical ... to generate multiple contrast images from a single scan and ... making it possible to both fine tune images and recreate ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ( ... "Advanced Wound Care Market by Type (Dressings, Therapy Devices, ... (In-Patient Facility, Out-Patient Facility), and Geography - Global Forecast ... --> --> The purpose ... and forecast of the global advanced wound care market. ...
Breaking Medicine Technology:
(Date:11/25/2015)... Indianapolis, IN (PRWEB) , ... November 25, 2015 ... ... clean water accessible for all, Water For Empowerment ™ attracts volunteers together ... on clean water by empowering women as key stakeholders in the process. The ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director ... about hair loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for ... and fuller hair, without the need for surgery, prescription pills, or topical foams. ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... people across the country to celebrate their sobriety and show through pictures what ... “before and after” photos this Thanksgiving with the hashtag #FacesOfGratitude on their Facebook, ...
(Date:11/25/2015)... ... 2015 , ... On November 23rd 2015 Cozy Products, a division ... business. Cozy Products explains what this means for business moving forward. , The Tri ... Products business model: to sell personal heaters that reduce energy consumption, are economical and ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by ... Chicago, IL, UV Angel is evaluating the efficacy of its product and its disinfection ... (totaling 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic ...
Breaking Medicine News(10 mins):